GAF
Cuban biopharmaceutical industry presented business opportunities
The group of companies in the biopharmaceutical sector of Cuba, BioCubaFarma, presented its portfolio of business opportunities for foreign investment during the first day of the II Business Forum of the Caribbean nation.
Cuban vaccines against Covid-19: Abdala, from the Center for Genetic Engineering and Biotechnology (CIGB); and Soberana 02 and Soberana Plus, from the Finlay Vaccine Institute (IFV) were the protagonists of the space. The panel made up of the first vice president of BioCubaFarma, Mayda Mauri; the Commercial and Business Director of that group, David Curbelo, as well as specialists from the research centers, offered details on the technological platforms used by immunogens and their industrial scaling. Said information is of interest by virtue of establishing alliances with large companies, a purpose of Cuban industries, which seek to grant commercial rights in a country or region, to carry out clinical trials and commercialize their products. During the presentation they highlighted that Soberana02 is the first vaccine worldwide used in young children, a population sector that in many parts of the planet is still waiting to be vaccinated. The product portfolio of the biotechnology sector of the Caribbean island contains other drugs that have proven their worth in Cuba and other nations.
